UK Markets closed

Biotest Aktiengesellschaft (0N6Z.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
43.60+0.40 (+0.93%)
At close: 4:45PM GMT
Full screen
Previous close43.20
Open43.70
Bid0.00 x N/A
Ask0.00 x N/A
Day's range43.60 - 43.70
52-week range43.60 - 43.70
Volume36
Avg. volumeN/A
Market cap1.57B
Beta (5Y monthly)0.52
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • EQS Group

    Biotest AG: Biotest AG opens seventh plasma collection centre in Czech Republic

    DGAP-News: Biotest AG / Key word(s): Miscellaneous25.11.2021 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest AG opens seventh plasma collection centre in Czech Republic- 27 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 25 November 2021. Biotest has received the operating license for its seventh plasma collection centre in Czech Republic from the country's national public health authority SUKL. The centre is locat

  • EQS Group

    Biotest AG: Biotest accelerates trimodulin development in hospitalized COVID-19 patients with federal funding in the volume of 29 million EUR

    DGAP-News: Biotest AG / Key word(s): Research Update23.11.2021 / 15:34 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest accelerates trimodulin development in hospitalized COVID-19 patients with federal funding in the volume of 29 million EUR- The German Federal Ministry of Education and Research (BMBF) and German Federal Ministry of Health (BMG) awarded Biotest's trimodulin project with financial support in the volume of €29 million- The funding allows B

  • EQS Group

    Biotest AG: Cytotect CP(R) Biotest activates immune cells that are crucial to control Cytomegalovirus

    DGAP-News: Biotest AG / Key word(s): Study results16.11.2021 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASECytotect CP(R) Biotest activates immune cells that are crucial to control Cytomegalovirus Cytomegalovirus (CMV) leads to severe complications in immunocompromised patients, particularly after transplantation Antiviral drugs suppress the production of new CMV particles in infected patients, but do not prevent initial infection of healthy cells nor